RAPP
Rapport Therapeutics Inc
NASDAQ · Pharmaceuticals
$27.09
+1.54 (+6.03%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 234.18M | 211.21M | 206.84M |
| Net Income | 54.92M | 48.45M | 43.47M |
| EPS | — | — | — |
| Profit Margin | 23.5% | 22.9% | 21.0% |
| Rev Growth | +10.7% | -0.4% | +18.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 431.14M | 385.28M | 429.96M |
| Total Equity | 595.66M | 606.41M | 607.00M |
| D/E Ratio | 0.72 | 0.64 | 0.71 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 80.71M | 80.88M | 78.48M |
| Free Cash Flow | 32.46M | 39.08M | 24.42M |